Why would Friedman join Synta at this point in his career... when he just retired?
Dr. Friedman’s appointment to the Board of Directors is also effective immediately. He was Chief Executive Officer of Incyte Corporation from 2001 until his retirement in January 2014. He continues to serve as a director of Incyte as well as Auxilium Pharmaceuticals, Durata Therapeutics, and two privately held companies.
Great post!!! And to those who are non believers.....you wont see talent of this caliber join an organization thats ready to fail. My prediction: the big players are loading the boat; a Partnership will be announced and a new CEO was required to make the deal. See you above $10 sooner than later.
furthermore... last insider sale still stands out in my mind when you consider what Safi, BK & Caxton are holding.
last i/s sale...
Jun 18, 2012 RIEDER WENDY E Officer
7,170 Direct Automatic Sale at $6 per share. 43,020
not one insider sale since... not even a tax sale?
in addition... % of Shares Held by All Insider and 5% Owners: 45%
Caxton (aka Kovner) is sitting on 28,641,849 shares
Kovner (aka Caxton) is sitting on 13,830,133 shares
at just $5 a share that's $212,359,910
"Waiting4kerx" Ref : "not one insider sale since... not even a tax sale"
Absolutely ! I have NEVER seen a pharma with many LARGE insiders BUYS ! And not options related.
This is VERY impressive. They absolutely can not all be wrong .
Sentiment: Strong Buy
The best case scenario:to broker a deal--partnership or buyout. Second best (stated) scenario: to vet a new CEO for a turnaround. He knows exactly what to look for. Why put his reputation on the line to join a company if the science isn't there? He's got millions of his own he doesn't need the money but he may be intrigued by the challenge and the science...